B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

SLC22A1

MOLECULAR TARGET

solute carrier family 22 member 1

UniProt: O15245NCBI Gene: 658018 compounds

SLC22A1 (solute carrier family 22 member 1) is targeted by 18 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting SLC22A1

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#CompoundConfidenceActive Assays
1Clonidine1.614
2Procainamide1.393
3Quinidine1.393
4Cimetidine1.102
5ethopropazine1.102
6Phenformin0.691
7Progesterone0.691
8Carvedilol0.691
9Chlorhexidine0.691
10Corticosterone0.691
11Dextrorphan Dextro form of levorphanol. It acts as0.691
12Dinoprost0.691
13Dinoprostone0.691
14Guanabenz0.691
15Ipratropium0.691
16Levorphanol0.691
17Pindolol0.691
18Pramipexole0.691

About SLC22A1 as a Drug Target

SLC22A1 (solute carrier family 22 member 1) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 18 compounds with documented SLC22A1 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

SLC22A1 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.